339 related articles for article (PubMed ID: 17962174)
1. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
Esper P; Gale D; Muehlbauer P
Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
Viale PH
Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
[TBL] [Abstract][Full Text] [Related]
3. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors.
Biedrzycki BA
ONS Connect; 2007; 22(8 Suppl):33-4. PubMed ID: 17824555
[No Abstract] [Full Text] [Related]
6. Targeted cancer. These "smart weapons" hit cancer in novel ways.
Held-Warmkessel J
Nursing; 2008 Sep; 38(9):26-32. PubMed ID: 18719487
[TBL] [Abstract][Full Text] [Related]
7. Clinical approaches to minimize rash associated with EGFR inhibitors.
Oishi K
Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxicity associated with cancer treatment.
Viale PH; Yamamoto DS
Clin J Oncol Nurs; 2008 Aug; 12(4):627-38. PubMed ID: 18676329
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies: a new generation of cancer treatments.
Gerber DE
Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies in breast cancer: challenging questions from oncology nurses.
Becze E
ONS Connect; 2007; 22(8 Suppl):31-2. PubMed ID: 17824554
[No Abstract] [Full Text] [Related]
12. Review: side effects of approved molecular targeted therapies in solid cancers.
Widakowich C; de Castro G; de Azambuja E; Dinh P; Awada A
Oncologist; 2007 Dec; 12(12):1443-55. PubMed ID: 18165622
[TBL] [Abstract][Full Text] [Related]
13. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
Reck M; Gutzmer R
Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapies in head and neck cancers: EGFR inhibitors.
Held-Warmkessel J
ONS News; 2006; 21(8 Suppl):61-2. PubMed ID: 16925156
[No Abstract] [Full Text] [Related]
15. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
Hammond-Thelin LA
Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
[TBL] [Abstract][Full Text] [Related]
18. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies: a nursing perspective.
Kay P
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous reactions associated with alpha interferon therapy.
Stafford-Fox V; Guindon KM
Clin J Oncol Nurs; 2000; 4(4):164-8. PubMed ID: 11261097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
